Order Article Reprints

Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, Lee D, Dai Z, Obot ER, Marks BM, et al. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for ²⁰³Pb and ²¹²Pb-Based Theranostics. Pharmaceutics. 2023; 15(2):414. https://doi.org/10.3390/pharmaceutics15020414

Li, Mengshi, Nicholas J. Baumhover, Dijie Liu, Brianna S. Cagle, Frédéric Boschetti, Guillaume Paulin, Dongyoul Lee, Zhiming Dai, Ephraim R. Obot, Brenna M. Marks, and et al. 2023. "Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for ²⁰³Pb and ²¹²Pb-Based Theranostics" Pharmaceutics 15, no. 2: 414. https://doi.org/10.3390/pharmaceutics15020414

Li, M., Baumhover, N. J., Liu, D., Cagle, B. S., Boschetti, F., Paulin, G., Lee, D., Dai, Z., Obot, E. R., Marks, B. M., Okeil, I., Sagastume, E. A., Gabr, M., Pigge, F. C., Johnson, F. L., & Schultz, M. K. (2023). Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for ²⁰³Pb and ²¹²Pb-Based Theranostics. Pharmaceutics, 15(2), 414. https://doi.org/10.3390/pharmaceutics15020414